Heart Attack Research Program: Platelet Sub-Study (HARP)

Launched by NYU LANGONE HEALTH · Jan 13, 2017

Keywords

ClinConnect Summary

The Heart Attack Research Program: Platelet Sub-Study (HARP) is looking to understand the role of platelets, which are small cells in our blood that help with clotting, in people who have had a heart attack. Specifically, the study will compare the platelets of men and women who experienced a heart attack—whether it’s due to blocked arteries or other reasons—with those of individuals who have stable chest pain (angina). This research will take place at NYU and Bellevue Medical Center, among other sites, and will involve collecting blood samples before and two months after the heart attack to analyze the platelets.

To be eligible for this study, participants must have had symptoms of a heart attack, such as chest pain, and show signs of heart damage through specific tests. Both men and women aged between 18 and 80 with certain health conditions related to heart attacks can participate, as long as they meet the study’s requirements and agree to all study procedures. If chosen, participants will undergo a cardiac catheterization, a procedure where doctors can see the heart's blood vessels, and provide blood samples for testing. It’s important to know that certain recent medical treatments or conditions might prevent someone from joining the study, so discussing eligibility with a healthcare provider is essential.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Acute ischemic symptoms compatible with diagnosis of MI, such as chest pain or anginal equivalent symptoms at rest or new onset exertional anginal equivalent symptoms
• * Objective evidence of MI (either or both of the following):
• • Elevation of troponin to above the laboratory upper limit of normal (ULN)
• • ST segment elevation of ≥1mm on 2 contiguous ECG leads
• • Willing to provide informed consent and comply with all aspects of the protocol
• • Administration of aspirin at least 1 hour before cardiac catheterization
• • Administration of thienopyridine (e.g., clopidogrel, ticagrelor) at least 1 hour before cardiac catheterization
• • Women and men with ≥50% of any major epicardial vessel on invasive angiography may participate
• Exclusion Criteria:
• • Recent use of vasospastic agents, such as cocaine, triptans, or ergot alkaloids (≤1 month)
• • Alternate explanation for troponin elevation, such as hypertensive urgency, acute exacerbation of heart failure, chronic elevation due to kidney disease, pulmonary embolism, cardiac trauma
• • Pregnancy
• • Thrombolytic therapy for STEMI (qualifying event)
• * Use of any of the following medications:
• • Platelet antagonists (except aspirin and thienopyridines) within 7 days
• • NSAIDs (e.g., ibuprofen, naproxen) within 3 days.
• • Thrombocytopenia (platelet count \<100,000)
• • Thrombocytosis (platelet count \>500,000)
• • Anemia (hemoglobin \<9 mg/dl)
• • Hemorrhagic diathesis